West Lafayette-based Inotiv Inc. (Nasdaq: NOTV) is acquiring Gateway Pharmacology Laboratories LLC in Missouri. The company says the acquisition is a strategic element of the its previously-announced St. Louis operations expansion.
The expansion is designed to include laboratories for increased drug metabolism and pharmacokinetics technology and capability.
“This acquisition of Gateway extends an array of in vivo capability and integrated laboratory support services at Inotiv to include cardiovascular and renal pharmacology,” said Scott Daniels, senior vice president of DMPK at Inotiv. “Moreover, the addition of Gateway’s expert team will enable us to assist clients’ early target validation activity as well as evaluate the efficacy and safety of new molecular entities designed for the treatment of kidney and heart disease.”
Financial terms of the deal were not disclosed.